Luc Cabel

3.8k total citations
81 papers, 1.9k citations indexed

About

Luc Cabel is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Luc Cabel has authored 81 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Oncology, 44 papers in Pulmonary and Respiratory Medicine and 36 papers in Cancer Research. Recurrent topics in Luc Cabel's work include Cancer Genomics and Diagnostics (24 papers), Advanced Breast Cancer Therapies (21 papers) and Cancer Immunotherapy and Biomarkers (13 papers). Luc Cabel is often cited by papers focused on Cancer Genomics and Diagnostics (24 papers), Advanced Breast Cancer Therapies (21 papers) and Cancer Immunotherapy and Biomarkers (13 papers). Luc Cabel collaborates with scholars based in France, United States and Belgium. Luc Cabel's co-authors include François‐Clément Bidard, Jean‐Yves Pierga, Charlotte Proudhon, Nicolas Kiavué, Delphine Loirat, Emanuela Romano, Ivan Bièche, Olivier Lantz, Antoine Vasseur and Marc‐Henri Stern and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Oncogene.

In The Last Decade

Luc Cabel

70 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Luc Cabel France 24 1.2k 924 599 487 236 81 1.9k
Neesha C. Dhani Canada 25 1.9k 1.6× 966 1.0× 435 0.7× 713 1.5× 311 1.3× 113 2.6k
Valentina Gambardella Spain 18 755 0.7× 485 0.5× 471 0.8× 474 1.0× 193 0.8× 85 1.5k
Eleni Andreopoulou United States 27 1.4k 1.2× 856 0.9× 568 0.9× 634 1.3× 138 0.6× 90 2.2k
Leticia De Mattos‐Arruda Spain 26 1.3k 1.1× 1.4k 1.5× 735 1.2× 947 1.9× 209 0.9× 54 2.7k
Ignacio Gil‐Bazo Spain 31 1.1k 1.0× 805 0.9× 1.0k 1.7× 1.2k 2.5× 244 1.0× 103 2.6k
Petros Nikolinakos United States 20 1.5k 1.3× 869 0.9× 986 1.6× 628 1.3× 404 1.7× 51 2.4k
Maria Giovanna Dal Bello Italy 27 1.3k 1.1× 509 0.6× 861 1.4× 636 1.3× 332 1.4× 86 2.1k
Gayle Jameson United States 19 944 0.8× 556 0.6× 399 0.7× 546 1.1× 119 0.5× 76 1.6k
Morten Mau‐Sørensen Denmark 28 1.2k 1.0× 541 0.6× 527 0.9× 1.1k 2.3× 276 1.2× 130 2.7k
Marie‐Christine Mathieu France 25 978 0.8× 705 0.8× 403 0.7× 461 0.9× 160 0.7× 63 2.1k

Countries citing papers authored by Luc Cabel

Since Specialization
Citations

This map shows the geographic impact of Luc Cabel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luc Cabel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luc Cabel more than expected).

Fields of papers citing papers by Luc Cabel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luc Cabel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luc Cabel. The network helps show where Luc Cabel may publish in the future.

Co-authorship network of co-authors of Luc Cabel

This figure shows the co-authorship network connecting the top 25 collaborators of Luc Cabel. A scholar is included among the top collaborators of Luc Cabel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luc Cabel. Luc Cabel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ramtohul, Toulsie, Lounes Djerroudi, Thomas Gaillard, et al.. (2025). Posttreatment MRI to Predict Pathologic Complete Response of Triple-Negative Breast Cancer to Neoadjuvant Chemoimmunotherapy. Radiology. 316(1). e243824–e243824.
2.
Cabel, Luc, Frédérique Berger, Thomas Bachelot, et al.. (2025). Kinetics and determinants of ESR1 mutation detection in metastatic breast cancer. Annals of Oncology. 37(3). 329–340.
3.
Santi, Daniel V., Gary W. Ashley, Luc Cabel, & François‐Clément Bidard. (2024). Could a Long-Acting Prodrug of SN-38 be Efficacious in Sacituzumab Govitecan-Resistant Tumors?. BioDrugs. 38(2). 171–176. 5 indexed citations
4.
Loirat, Delphine, Nicolas Kiavué, Diana Bello Roufai, et al.. (2024). Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals: efficacy, safety, and impact of brain metastases. Breast Cancer. 31(4). 572–580. 11 indexed citations
5.
Tsai, Chun‐Ming, Luc Cabel, Enrico Moiso, et al.. (2024). 418P Concordance of PI3K-AKT pathway alterations between tumor and ctDNA in metastatic breast cancer. Annals of Oncology. 35. S395–S396.
6.
Cabel, Luc, Benoîte Méry, Mathieu Kuentz, et al.. (2024). 238MO PROMENADE: PembROlizuMab for early triple negative ER-low breast caNcer, reAl worlD frEnch cohort. Annals of Oncology. 35. S312–S313. 4 indexed citations
7.
Moiso, Enrico, Emanuela Ferraro, Luc Cabel, et al.. (2024). Predicting CDK4/6 inhibitors outcomes in pts with HR+/HER2- metastatic breast cancer: A machine learning approach.. Journal of Clinical Oncology. 42(16_suppl). 1074–1074. 1 indexed citations
8.
Ramtohul, Toulsie, Claire Bonneau, Emmanuelle Menet, et al.. (2024). Use of Pretreatment Perfusion MRI–based Intratumoral Heterogeneity to Predict Pathologic Response of Triple-Negative Breast Cancer to Neoadjuvant Chemoimmunotherapy. Radiology. 312(3). e240575–e240575. 14 indexed citations
9.
Cabel, Luc, David M. Kurtz, Daniel W. Ross, et al.. (2024). 293P Ultra-sensitive ctDNA detection and monitoring in early breast cancer using PhasED-Seq. Annals of Oncology. 35. S338–S338. 1 indexed citations
10.
Bidard, François‐Clément, Nicolas Kiavué, William Jacot, et al.. (2023). Overall Survival With Circulating Tumor Cell Count–Driven Choice of Therapy in Advanced Breast Cancer: A Randomized Trial. Journal of Clinical Oncology. 42(4). 383–389. 28 indexed citations
11.
Phan, Duc T. T., Danilo Maddalo, Luc Cabel, et al.. (2023). Bridging the gap between tumor-on-chip and clinics: a systematic review of 15 years of studies. Lab on a Chip. 23(18). 3906–3935. 27 indexed citations
12.
Frenel, Jean‐Sébastien, Amélie Lusque, Suzette Delaloge, et al.. (2023). Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation. British Journal of Cancer. 128(11). 2072–2080. 3 indexed citations
13.
Seban, Romain‐David, et al.. (2023). Clinical Utility of Pre-Therapeutic [18F]FDG PET/CT Imaging for Predicting Outcomes in Breast Cancer. Journal of Clinical Medicine. 12(17). 5487–5487. 3 indexed citations
14.
Stern, Marc‐Henri, Nicolas Kiavué, Luc Cabel, et al.. (2022). Microsatellite instability detection in breast cancer using drop-off droplet digital PCR. Oncogene. 41(49). 5289–5297. 12 indexed citations
15.
Cabel, Luc, Claire Bonneau, Alice Bernard‐Tessier, et al.. (2021). HPV ctDNA detection of high-risk HPV types during chemoradiotherapy for locally advanced cervical cancer. ESMO Open. 6(3). 100154–100154. 41 indexed citations
16.
Jeannot, Emmanuelle, Lauren Darrigues, Marc Michel, et al.. (2020). A single droplet digital PCR for ESR1 activating mutations detection in plasma. Oncogene. 39(14). 2987–2995. 42 indexed citations
17.
Melaabi, Samia, et al.. (2019). ESR1 Mutation Detection and Dynamics in Meningeal Carcinomatosis in Breast Cancer. Journal of Breast Cancer. 23(2). 218–218. 5 indexed citations
18.
Cabel, Luc, Emmanuelle Jeannot, Ivan Bièche, et al.. (2018). Prognostic Impact of Residual HPV ctDNA Detection after Chemoradiotherapy for Anal Squamous Cell Carcinoma. Clinical Cancer Research. 24(22). 5767–5771. 65 indexed citations
19.
Cabel, Luc, Charlotte Proudhon, Emanuela Romano, et al.. (2018). Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy. Nature Reviews Clinical Oncology. 15(10). 639–650. 151 indexed citations
20.
Saidu, Nathaniel Edward Bennett, Gaëlle Noé, Olivier Cerles, et al.. (2017). Dimethyl Fumarate Controls the NRF2/DJ-1 Axis in Cancer Cells: Therapeutic Applications. Molecular Cancer Therapeutics. 16(3). 529–539. 59 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Neesha C. Dhani Breakdown of academic impact, for papers by Valentina Gambardella Breakdown of academic impact, for papers by Eleni Andreopoulou Breakdown of academic impact, for papers by Leticia De Mattos‐Arruda Breakdown of academic impact, for papers by Ignacio Gil‐Bazo Breakdown of academic impact, for papers by Petros Nikolinakos Breakdown of academic impact, for papers by Maria Giovanna Dal Bello Breakdown of academic impact, for papers by Gayle Jameson Breakdown of academic impact, for papers by Morten Mau‐Sørensen Breakdown of academic impact, for papers by Marie‐Christine Mathieu
Rankless by CCL
2026